Navigation Links
Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
Date:3/20/2008

SEATTLE, March 20 /PRNewswire/ -- Fred Hutchinson Cancer Research Center (FHCRC) and NSB POSTECH, Inc. (NSB) have reached a collaboration agreement to coordinate their efforts and to determine the efficacy of the NSB's NanoCones surface technology in creating high quality proteomic microarrays to be used in the study of human diseases.

NSB is a South Korean biotech company which possesses a proprietary microarray technology and a great deal of expertise in nano-scale controlled surface chemistry. NSB has agreed to fund the collaboration.

Announced today, this collaboration will involve a comparison of slides created with NSB's newly developed NanoCones surface technology and the current industry standard.

"This is the first time a Korean biotech company has had an opportunity to collaborate with a major U.S.-based cancer research center. We are very thrilled to be working with scientists at the Hutchinson Center," said Dr. Joon Won Park, president of NSB and one of the inventors of the NanoCones technology.

"We are excited about the preliminary data that has been generated when antibodies were arrayed using the NanoCones technology. We hope this will make our antibody arrays more sensitive and accurate," said Dr. Paul Lampe, member of the Hutchinson Center's Public Health Sciences Division and associate program head of molecular diagnostics.

Antibody or protein microarrays are glass microscope slides onto which very small amounts of thousands of different antibodies or proteins have been affixed at distinct locations. Antibody microarrays can be used to simultaneously determine the level of each antibody's specific binding partner in complex mixtures such as blood so thousands of different assays can be performed with small amounts of sample.

At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS an
'/>"/>

SOURCE NSB POSTECH, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Demanding industrial and ... engineered of synthetic Sapphire and Glass Ball Lenses, now ... Swiss Jewel Company , of Philadelphia , PA. ... and collimating the light beams without the need for ... and natural durability (9 mohs) make it the ideal ...
(Date:6/18/2013)... 18, 2013 RegeneCure announced ...  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a ... A common problem encountered when patients have a tooth replaced ... volume to house the implant. Consequently there is often a ... the natural bone regenerates. The bone substitute material, in turn, ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... June 18, 2013 This webinar ... pharmaceutical advertising and promotion, and review the basic ... learn how to apply these principles through real ... ,     The fundamentals on FDA regulations and ... labeling ,     Assessing traditional and newer forms ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Novocell, Inc. , a preclinical stage diabetes ... award totaling $20 million from the California Institute for Regenerative ... scientists at the University of California, San Francisco (UCSF), led ... million. The funding will advance Novocell,s development of a first ...
... Nev., Oct. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: ... a $300 million securitization transaction intended to monetize certain ... closing of the transaction, which is expected to occur ... QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary ...
... Novavax, Inc. (Nasdaq: NVAX ) announced ... joint venture between Cadila Pharmaceuticals in India, has ... will be used to produce pandemic and seasonal ... virus-like particle (VLP) vaccine technology to produce commercial-scale ...
Cached Biology Technology:Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 5
(Date:6/18/2013)... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ... the ten largest recorded. That would range from an ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... sites of fundamental geodynamic, geochemical and biological processes and ... for us. Scientific marine drilling and coring is crucial ... (sub-) seafloors to advance our knowledge in the Earth ... (ESF) European Collaborative Research (EUROCORES) programme EuroMARC is an ...
... Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. ... Nature Medicine that supports the broad ... antibody platform, showing that its PS-targeting drug bavituximab ... models. Bavituximab is in clinical ...
... Futronic Technology Company Limited, a,global provider of ... of FS22, a high performance fingerprint access and,attendance ... launched,FS21M (mid-range device) and FS20 (low cost device), ... and attendance control device.,FS22 uses a powerful Digital ...
Cached Biology News:Europe cores in EUROCORES: Ocean drilling in EuroMARC 2Europe cores in EUROCORES: Ocean drilling in EuroMARC 3Europe cores in EUROCORES: Ocean drilling in EuroMARC 4Europe cores in EUROCORES: Ocean drilling in EuroMARC 5Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Futronic Launches FS22 Fingerprint Access Control Device 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
Biology Products: